| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
134,746,000 |
| Market
Cap: |
1.52(B) |
| Last
Volume: |
3,983,089 |
Avg
Vol: |
3,972,076 |
| 52
Week Range: |
$10.85 - $14.99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 457 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Dynavax Technologies is a commercial stage biopharmaceutical company engaged in developing and commercializing vaccines. Co.'s primary marketed product, Hepatitis B Vaccine (Recombinant), Adjuvanted (HEPLISAV-B), is approved in the U.S. and European Union for prevention of infection caused by known subtypes of hepatitis B virus in adults age 18 years and older. Co. also manufactures and sells CpG oligonucleotide (CpG) 1018 adjuvant, the vaccine adjuvant used in HEPLISAV-B. Co. developed CpG 1018 adjuvant to provide an increased vaccine immune response.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
20,526 |
51,026 |
3,223,914 |
7,930,135 |
| Total Sell Value |
$262,322 |
$686,072 |
$41,730,883 |
$106,117,062 |
| Total People Sold |
1 |
3 |
4 |
6 |
| Total Sell Transactions |
1 |
4 |
17 |
31 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Novack David F |
Senior Vice President |
• – – |
2014-03-11 |
4 |
A |
$1.81 |
$362,000 |
D/D |
200,000 |
200,000 |
|
- |
|
| Phillips Peggy V |
Director |
– • – |
2013-10-30 |
4 |
B |
$1.08 |
$100,000 |
D/D |
93,023 |
138,023 |
2.39 |
- |
|
| Oronsky Arnold L |
Director |
– • – |
2013-10-30 |
4 |
B |
$1.08 |
$200,001 |
D/D |
186,047 |
375,055 |
2.39 |
- |
|
| Kisner Daniel L |
Director |
– • – |
2013-10-30 |
4 |
B |
$1.08 |
$10,750 |
I/I |
10,000 |
15,000 |
2.1 |
- |
|
| Janssen Robert |
Chief Medical Officer and VPOf |
• – – |
2013-07-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,481 |
|
- |
|
| Novack David F |
Senior Vice PresidentOfficer |
• – – |
2013-03-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,500 |
|
- |
|
| Tuck Stephen F |
VP, Global Technical Ops |
• – – |
2013-01-15 |
4 |
D |
$3.04 |
$75,003 |
D/D |
(24,672) |
106,151 |
|
- |
|
| Tuck Stephen F |
VP, Global Technical Ops |
• – – |
2013-01-15 |
4 |
OE |
$1.50 |
$75,000 |
D/D |
50,000 |
130,823 |
|
- |
|
| Coffman Robert |
Chief Scientific Officer & VP |
• – – |
2012-12-18 |
4 |
D |
$2.86 |
$29,890 |
D/D |
(10,451) |
47,467 |
|
- |
|
| Coffman Robert |
Chief Scientific Officer & VP |
• – – |
2012-12-18 |
4 |
OE |
$1.50 |
$29,889 |
D/D |
19,926 |
57,918 |
|
- |
|
| Martin J Tyler |
President, CMO & Director |
• • – |
2012-11-16 |
4 |
OE |
$1.58 |
$56,499 |
D/D |
35,759 |
222,089 |
|
- |
|
| Coffman Robert |
Chief Scientific Officer & VP |
• – – |
2012-11-06 |
4 |
AS |
$4.31 |
$34,480 |
D/D |
(8,000) |
19,926 |
|
- |
|
| Kessel Mark |
Director |
– • – |
2012-10-16 |
4 |
S |
$4.73 |
$28,356,000 |
I/I |
(6,000,000) |
3,031,431 |
|
- |
|
| Coffman Robert |
Chief Scientific Officer & VP |
• – – |
2012-10-05 |
4 |
AS |
$4.86 |
$24,094 |
D/D |
(4,889) |
37,992 |
|
- |
|
| Coffman Robert |
Chief Scientific Officer & VP |
• – – |
2012-10-05 |
4 |
AS |
$4.96 |
$15,431 |
I/I |
(3,111) |
0 |
|
- |
|
| Coffman Robert |
Chief Scientific Officer & VP |
• – – |
2012-10-05 |
4 |
D |
$4.86 |
$3,378 |
D/D |
(695) |
42,881 |
|
- |
|
| Tuck Stephen F |
VP, Global Technical Ops |
• – – |
2012-10-03 |
4 |
D |
$4.81 |
$132,323 |
D/D |
(27,510) |
80,823 |
|
- |
|
| Tuck Stephen F |
VP, Global Technical Ops |
• – – |
2012-10-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
75,000 |
108,333 |
|
- |
|
| Lew Jennifer |
VP, Finance & PAO |
• – – |
2012-09-14 |
4 |
S |
$4.53 |
$84,938 |
D/D |
(18,750) |
2,332 |
|
- |
|
| Lew Jennifer |
VP, Finance & PAO |
• – – |
2012-09-14 |
4 |
OE |
$0.54 |
$10,125 |
D/D |
18,750 |
21,082 |
|
- |
|
| Coffman Robert |
Chief Scientific Officer & VP |
• – – |
2012-09-13 |
4 |
AS |
$4.52 |
$36,160 |
I/I |
(8,000) |
3,111 |
|
- |
|
| Coffman Robert |
Chief Scientific Officer & VP |
• – – |
2012-09-05 |
4 |
OE |
$4.06 |
$65,360 |
D/D |
16,000 |
25,325 |
|
- |
|
| Coffman Robert |
Chief Scientific Officer & VP |
• – – |
2012-06-20 |
4 |
OE |
$4.13 |
$33,014 |
D/D |
8,000 |
41,325 |
|
- |
|
| Coffman Robert |
Chief Scientific Officer & VP |
• – – |
2012-05-01 |
4 |
D |
$5.08 |
$91,519 |
D/D |
(18,000) |
49,325 |
|
- |
|
| Ostrach Michael S |
VP, CBO, and General Counsel |
• – – |
2012-05-01 |
4 |
D |
$5.16 |
$57,028 |
D/D |
(11,052) |
87,720 |
|
- |
|
423 Records found
|
|
Page 12 of 17 |
|
|
0.24 (2.17%) 
